Cargando…

Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy

BACKGROUND: Reports on the clinical meaningfulness of outcome measures in spinal muscular atrophy (SMA) are rare. In this two-part study, our aim was to explore patients’ and caregivers’ views on the clinical relevance of the Hammersmith Functional Motor Scale Expanded- (HFMSE). METHODS: First, we u...

Descripción completa

Detalles Bibliográficos
Autores principales: Pera, Maria C., Coratti, Giorgia, Forcina, Nicola, Mazzone, Elena S., Scoto, Mariacristina, Montes, Jacqueline, Pasternak, Amy, Mayhew, Anna, Messina, Sonia, Sframeli, Maria, Main, Marion, Lofra, Robert Muni, Duong, Tina, Ramsey, Danielle, Dunaway, Sally, Salazar, Rachel, Fanelli, Lavinia, Civitello, Matthew, de Sanctis, Roberto, Antonaci, Laura, Lapenta, Leonardo, Lucibello, Simona, Pane, Marika, Day, John, Darras, Basil T., De Vivo, Darryl C., Muntoni, Francesco, Finkel, Richard, Mercuri, Eugenio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5324197/
https://www.ncbi.nlm.nih.gov/pubmed/28231823
http://dx.doi.org/10.1186/s12883-017-0790-9
_version_ 1782510175988482048
author Pera, Maria C.
Coratti, Giorgia
Forcina, Nicola
Mazzone, Elena S.
Scoto, Mariacristina
Montes, Jacqueline
Pasternak, Amy
Mayhew, Anna
Messina, Sonia
Sframeli, Maria
Main, Marion
Lofra, Robert Muni
Duong, Tina
Ramsey, Danielle
Dunaway, Sally
Salazar, Rachel
Fanelli, Lavinia
Civitello, Matthew
de Sanctis, Roberto
Antonaci, Laura
Lapenta, Leonardo
Lucibello, Simona
Pane, Marika
Day, John
Darras, Basil T.
De Vivo, Darryl C.
Muntoni, Francesco
Finkel, Richard
Mercuri, Eugenio
author_facet Pera, Maria C.
Coratti, Giorgia
Forcina, Nicola
Mazzone, Elena S.
Scoto, Mariacristina
Montes, Jacqueline
Pasternak, Amy
Mayhew, Anna
Messina, Sonia
Sframeli, Maria
Main, Marion
Lofra, Robert Muni
Duong, Tina
Ramsey, Danielle
Dunaway, Sally
Salazar, Rachel
Fanelli, Lavinia
Civitello, Matthew
de Sanctis, Roberto
Antonaci, Laura
Lapenta, Leonardo
Lucibello, Simona
Pane, Marika
Day, John
Darras, Basil T.
De Vivo, Darryl C.
Muntoni, Francesco
Finkel, Richard
Mercuri, Eugenio
author_sort Pera, Maria C.
collection PubMed
description BACKGROUND: Reports on the clinical meaningfulness of outcome measures in spinal muscular atrophy (SMA) are rare. In this two-part study, our aim was to explore patients’ and caregivers’ views on the clinical relevance of the Hammersmith Functional Motor Scale Expanded- (HFMSE). METHODS: First, we used focus groups including SMA patients and caregivers to explore their views on the clinical relevance of the individual activities included in the HFMSE. Then we asked caregivers to comment on the clinical relevance of possible changes of HFMSE scores over time. As functional data of individual patients were available, some of the questions were tailored according to their functional level on the HFMSE. RESULTS: Part 1: Sixty-three individuals participated in the focus groups. This included 30 caregivers, 25 patients and 8 professionals who facilitated the discussion. The caregivers provided a comparison to activities of daily living for each of the HFMSE items. Part 2: One hundred and forty-nine caregivers agreed to complete the questionnaire: in response to a general question, 72% of the caregivers would consider taking part in a clinical trial if the treatment was expected to slow down deterioration, 88% if it would stop deterioration and 97% if the treatment was expected to produce an improvement. Caregivers were informed of the first three items that their child could not achieve on the HFMSE. In response 75% indicated a willingness to take part in a clinical trial if they could achieve at least one of these abilities, 89% if they could achieve two, and 100% if they could achieve more than 2. CONCLUSIONS: Our findings support the use of the HFMSE as a key outcome measure in SMA clinical trials because the individual items and the detected changes have clear content validity and clinical meaningfulness for patients and their caregivers. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12883-017-0790-9) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5324197
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-53241972017-03-01 Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy Pera, Maria C. Coratti, Giorgia Forcina, Nicola Mazzone, Elena S. Scoto, Mariacristina Montes, Jacqueline Pasternak, Amy Mayhew, Anna Messina, Sonia Sframeli, Maria Main, Marion Lofra, Robert Muni Duong, Tina Ramsey, Danielle Dunaway, Sally Salazar, Rachel Fanelli, Lavinia Civitello, Matthew de Sanctis, Roberto Antonaci, Laura Lapenta, Leonardo Lucibello, Simona Pane, Marika Day, John Darras, Basil T. De Vivo, Darryl C. Muntoni, Francesco Finkel, Richard Mercuri, Eugenio BMC Neurol Research Article BACKGROUND: Reports on the clinical meaningfulness of outcome measures in spinal muscular atrophy (SMA) are rare. In this two-part study, our aim was to explore patients’ and caregivers’ views on the clinical relevance of the Hammersmith Functional Motor Scale Expanded- (HFMSE). METHODS: First, we used focus groups including SMA patients and caregivers to explore their views on the clinical relevance of the individual activities included in the HFMSE. Then we asked caregivers to comment on the clinical relevance of possible changes of HFMSE scores over time. As functional data of individual patients were available, some of the questions were tailored according to their functional level on the HFMSE. RESULTS: Part 1: Sixty-three individuals participated in the focus groups. This included 30 caregivers, 25 patients and 8 professionals who facilitated the discussion. The caregivers provided a comparison to activities of daily living for each of the HFMSE items. Part 2: One hundred and forty-nine caregivers agreed to complete the questionnaire: in response to a general question, 72% of the caregivers would consider taking part in a clinical trial if the treatment was expected to slow down deterioration, 88% if it would stop deterioration and 97% if the treatment was expected to produce an improvement. Caregivers were informed of the first three items that their child could not achieve on the HFMSE. In response 75% indicated a willingness to take part in a clinical trial if they could achieve at least one of these abilities, 89% if they could achieve two, and 100% if they could achieve more than 2. CONCLUSIONS: Our findings support the use of the HFMSE as a key outcome measure in SMA clinical trials because the individual items and the detected changes have clear content validity and clinical meaningfulness for patients and their caregivers. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12883-017-0790-9) contains supplementary material, which is available to authorized users. BioMed Central 2017-02-23 /pmc/articles/PMC5324197/ /pubmed/28231823 http://dx.doi.org/10.1186/s12883-017-0790-9 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Pera, Maria C.
Coratti, Giorgia
Forcina, Nicola
Mazzone, Elena S.
Scoto, Mariacristina
Montes, Jacqueline
Pasternak, Amy
Mayhew, Anna
Messina, Sonia
Sframeli, Maria
Main, Marion
Lofra, Robert Muni
Duong, Tina
Ramsey, Danielle
Dunaway, Sally
Salazar, Rachel
Fanelli, Lavinia
Civitello, Matthew
de Sanctis, Roberto
Antonaci, Laura
Lapenta, Leonardo
Lucibello, Simona
Pane, Marika
Day, John
Darras, Basil T.
De Vivo, Darryl C.
Muntoni, Francesco
Finkel, Richard
Mercuri, Eugenio
Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy
title Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy
title_full Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy
title_fullStr Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy
title_full_unstemmed Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy
title_short Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy
title_sort content validity and clinical meaningfulness of the hfmse in spinal muscular atrophy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5324197/
https://www.ncbi.nlm.nih.gov/pubmed/28231823
http://dx.doi.org/10.1186/s12883-017-0790-9
work_keys_str_mv AT peramariac contentvalidityandclinicalmeaningfulnessofthehfmseinspinalmuscularatrophy
AT corattigiorgia contentvalidityandclinicalmeaningfulnessofthehfmseinspinalmuscularatrophy
AT forcinanicola contentvalidityandclinicalmeaningfulnessofthehfmseinspinalmuscularatrophy
AT mazzoneelenas contentvalidityandclinicalmeaningfulnessofthehfmseinspinalmuscularatrophy
AT scotomariacristina contentvalidityandclinicalmeaningfulnessofthehfmseinspinalmuscularatrophy
AT montesjacqueline contentvalidityandclinicalmeaningfulnessofthehfmseinspinalmuscularatrophy
AT pasternakamy contentvalidityandclinicalmeaningfulnessofthehfmseinspinalmuscularatrophy
AT mayhewanna contentvalidityandclinicalmeaningfulnessofthehfmseinspinalmuscularatrophy
AT messinasonia contentvalidityandclinicalmeaningfulnessofthehfmseinspinalmuscularatrophy
AT sframelimaria contentvalidityandclinicalmeaningfulnessofthehfmseinspinalmuscularatrophy
AT mainmarion contentvalidityandclinicalmeaningfulnessofthehfmseinspinalmuscularatrophy
AT lofrarobertmuni contentvalidityandclinicalmeaningfulnessofthehfmseinspinalmuscularatrophy
AT duongtina contentvalidityandclinicalmeaningfulnessofthehfmseinspinalmuscularatrophy
AT ramseydanielle contentvalidityandclinicalmeaningfulnessofthehfmseinspinalmuscularatrophy
AT dunawaysally contentvalidityandclinicalmeaningfulnessofthehfmseinspinalmuscularatrophy
AT salazarrachel contentvalidityandclinicalmeaningfulnessofthehfmseinspinalmuscularatrophy
AT fanellilavinia contentvalidityandclinicalmeaningfulnessofthehfmseinspinalmuscularatrophy
AT civitellomatthew contentvalidityandclinicalmeaningfulnessofthehfmseinspinalmuscularatrophy
AT desanctisroberto contentvalidityandclinicalmeaningfulnessofthehfmseinspinalmuscularatrophy
AT antonacilaura contentvalidityandclinicalmeaningfulnessofthehfmseinspinalmuscularatrophy
AT lapentaleonardo contentvalidityandclinicalmeaningfulnessofthehfmseinspinalmuscularatrophy
AT lucibellosimona contentvalidityandclinicalmeaningfulnessofthehfmseinspinalmuscularatrophy
AT panemarika contentvalidityandclinicalmeaningfulnessofthehfmseinspinalmuscularatrophy
AT dayjohn contentvalidityandclinicalmeaningfulnessofthehfmseinspinalmuscularatrophy
AT darrasbasilt contentvalidityandclinicalmeaningfulnessofthehfmseinspinalmuscularatrophy
AT devivodarrylc contentvalidityandclinicalmeaningfulnessofthehfmseinspinalmuscularatrophy
AT muntonifrancesco contentvalidityandclinicalmeaningfulnessofthehfmseinspinalmuscularatrophy
AT finkelrichard contentvalidityandclinicalmeaningfulnessofthehfmseinspinalmuscularatrophy
AT mercurieugenio contentvalidityandclinicalmeaningfulnessofthehfmseinspinalmuscularatrophy